PhytoHealth’s rAPS®refined Polysaccharides of Astragalus membranaceus Research Center Has Applied for a PCT International Patent for Its successful results

Studies have shown that the targeted therapy combined with the patented formula of rAPS®refined Polysaccharides of Astragalus membranaceus can enhance the cytotoxicity of anti-cancer medicine in drug-resistant cancer cell lines, up to 6.5 times in a higher dose group.(Photo provided by PhytoHealth)

The "rAPS® Refined Polysaccharides of Astragalus membranaceus Research Center" under PhytoHealth Corporation (4108) has been dedicated to Astragalus research for over two decades. Utilizing advanced technology, the center extracts the active ingredient, rAPS® Refined Astragalus Polysaccharides, from Astragalus membranaceus for cancer research. Studies indicate that targeted therapy, in conjunction with the patented rAPS® formula, enhances the efficacy against drug-resistant cancer cells. The survival rate of these cells is over six times higher than the control group. Recently, both international and domestic PCT patents have been applied for this innovation.

From the right are General Manager- Angel Lee, Chairman- Lee Yi-Li, and the founder Lee Cheng-Chia of PhytoHealth Corporation(Photo provided by PhytoHealth)

Astragalus membranaceus, recognized in the Pharmacopoeia of the World Health Organization and advanced countries, is the source of rAPS®. This active ingredient is extracted, separated, purified, and refined using proprietary patented technology. The refined plant material is then used to produce injections that have successfully passed clinical trials and received the first new drug permit issued in Taiwan. The drug is indicated for "Cancer-Related Fatigue (CRF)" and is listed as a treatment option in the "Management of Cancer-Related Fatigue - A Guideline for Taiwan" compiled by medical professionals.

PhytoHealth's Research Center, in collaboration with various industry-academic institutions, is conducting in-depth research on the effects of refined Astragalus polysaccharides on cancer cells, including combination therapy with multiple cancer drugs. One of the significant challenges in cancer treatment is drug resistance. A study on the lung cancer cell line (H1975) examined the potential of the targeted drug, combined with the patented formula of refined Astragalus polysaccharide, to enhance the response of "drug-resistant cancer cells" to the targeted drug, thereby increasing the sensitivity of cancer cells to the targeted drug. The study found that the survival rate of drug-resistant cancer cells dropped to 8.8% after 72 hours when using both treatments together, compared to 57% in the control group using only the targeted therapy (Tarceva). This difference is nearly 6.5 times. Furthermore, a positive correlation was observed between dosage and effect: the higher the dosage, the greater the sensitivity of drug-resistant cancer cells to the targeted therapy. This significant achievement marks another milestone in cancer treatment.

 Angel Lee, General Manager of PhytoHealth, stated that rAPS® Refined Astragalus Polysaccharides has proven effective in treating Cancer-Related Fatigue and significantly improving the quality of life for cancer patients. PhytoHealth continues to collaborate with experts from various industries and national laboratories for deeper research on cancer combination therapy and its potential applications in various disease fields, including the aforementioned combination therapy and ongoing immunotherapy combined treatment. Through the research and development of these products, PhytoHealth aims to bring successful results to benefit all cancer patients.

The original article:《工商時報》懷特「rAPS ®精製黃耆多醣」研究中心 最新成果申請PCT國際專利